Sex differences in body composition in youth with type 1 diabetes and its predictive value in cardiovascular disease risk assessment.
children and adolescents
glycaemic control
muscle-to-fat ratio
sarcopenic obesity
type 1 diabetes
Journal
Diabetes/metabolism research and reviews
ISSN: 1520-7560
Titre abrégé: Diabetes Metab Res Rev
Pays: England
ID NLM: 100883450
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
06
09
2022
received:
21
07
2022
accepted:
10
10
2022
pubmed:
22
10
2022
medline:
10
1
2023
entrez:
21
10
2022
Statut:
ppublish
Résumé
Women with type 1 diabetes (T1D) are more susceptible than men to cardiovascular disease (CVD). Signs of increased risk may already appear among adolescent girls. We explored the contribution of body composition to the development of CVD risk factors among youth with T1D. One hundred and eighty nine subjects with T1D (mean age 15.3 ± 5.1 years, 55% boys) followed between January 2018-January 2022 were included in this observational study. Sociodemographic and clinical data were extracted from medical files. Body composition was measured by bioelectrical impedance analysis, and muscle-to-fat ratio (MFR) z-scores were calculated. Logistic regression model assessed the association between body composition (MFR z-scores) and evidence of CVD risk factors. Females were characterised by higher median BMI z-scores (0.47 vs. 0.04, p = 0.012), higher fat and truncal fat percentage levels (p ≤ 0.001) and lower median MFR z-scores (-0.64 vs. -0.25, p ≤ 0.001), higher median triglyceride (TG) levels (71 vs. 61 mg/dl, p = 0.05), longer disease duration to initiation of insulin pump therapy (p = 0.041), and more time spent in marked hypoglycemia (1 vs. 0.2%, p = 0.007) than males. Males' MFR z-scores were associated with several diabetes-related parameters (age at diagnosis, CGM metrics, HbA1c and insulin dose), while the females'' MFR z-scores were linked to the atherogenic dyslipidemia index (TG:HDL ratio). The odds for CVD risk factors were doubled for every 1 SD decrease in MFR z-score (OR = 0.50, CI [0.30-0.84], p = 0.009) and also increased with age (OR = 1.07, CI [1.004-1.148], p = 0.038). Body composition measurement has a predictive value in CVD risk assessment in youth with T1D, with unique characteristics and influences in each sex.
Sections du résumé
BACKGROUND
Women with type 1 diabetes (T1D) are more susceptible than men to cardiovascular disease (CVD). Signs of increased risk may already appear among adolescent girls.
OBJECTIVES
We explored the contribution of body composition to the development of CVD risk factors among youth with T1D.
METHODS
One hundred and eighty nine subjects with T1D (mean age 15.3 ± 5.1 years, 55% boys) followed between January 2018-January 2022 were included in this observational study. Sociodemographic and clinical data were extracted from medical files. Body composition was measured by bioelectrical impedance analysis, and muscle-to-fat ratio (MFR) z-scores were calculated. Logistic regression model assessed the association between body composition (MFR z-scores) and evidence of CVD risk factors.
RESULTS
Females were characterised by higher median BMI z-scores (0.47 vs. 0.04, p = 0.012), higher fat and truncal fat percentage levels (p ≤ 0.001) and lower median MFR z-scores (-0.64 vs. -0.25, p ≤ 0.001), higher median triglyceride (TG) levels (71 vs. 61 mg/dl, p = 0.05), longer disease duration to initiation of insulin pump therapy (p = 0.041), and more time spent in marked hypoglycemia (1 vs. 0.2%, p = 0.007) than males. Males' MFR z-scores were associated with several diabetes-related parameters (age at diagnosis, CGM metrics, HbA1c and insulin dose), while the females'' MFR z-scores were linked to the atherogenic dyslipidemia index (TG:HDL ratio). The odds for CVD risk factors were doubled for every 1 SD decrease in MFR z-score (OR = 0.50, CI [0.30-0.84], p = 0.009) and also increased with age (OR = 1.07, CI [1.004-1.148], p = 0.038).
CONCLUSIONS
Body composition measurement has a predictive value in CVD risk assessment in youth with T1D, with unique characteristics and influences in each sex.
Identifiants
pubmed: 36269559
doi: 10.1002/dmrr.3584
pmc: PMC10078230
doi:
Substances chimiques
Insulin
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3584Informations de copyright
© 2022 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.
Références
World J Diabetes. 2021 Jan 15;12(1):56-68
pubmed: 33520108
Vital Health Stat 11. 2002 May;(246):1-190
pubmed: 12043359
J Diabetes Res. 2015;2015:916585
pubmed: 25883987
Arch Dis Child. 1970 Feb;45(239):13-23
pubmed: 5440182
Curr Opin Clin Nutr Metab Care. 2008 Sep;11(5):566-72
pubmed: 18685451
Hypertension. 2018 Jun;71(6):1269-1324
pubmed: 29133354
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
Pediatr Diabetes. 2018 Oct;19 Suppl 27:205-226
pubmed: 30133095
Diabetes Metab Res Rev. 2023 Jan;39(1):e3584
pubmed: 36269559
Acta Diabetol. 2021 Feb;58(2):145-152
pubmed: 32915299
Diabetes Care. 2007 Aug;30(8):2098-100
pubmed: 17468347
Front Endocrinol (Lausanne). 2022 Jun 01;13:914740
pubmed: 35721709
Diabetes Care. 2011 Nov;34(11):2356-9
pubmed: 21926289
PLoS One. 2016 Oct 3;11(10):e0162960
pubmed: 27695110
Int J Mol Sci. 2022 Jan 12;23(2):
pubmed: 35054972
Curr Obes Rep. 2019 Dec;8(4):458-471
pubmed: 31654335
PLoS One. 2017 May 10;12(5):e0177210
pubmed: 28489876
Arch Dis Child. 1969 Jun;44(235):291-303
pubmed: 5785179
Am J Physiol Endocrinol Metab. 2020 Jan 1;318(1):E44-E51
pubmed: 31794260
Obes Med. 2018 Mar;9:21-31
pubmed: 29984330
Endocr Pract. 2017 Apr;23(Suppl 2):1-87
pubmed: 28437620
Natl Health Stat Report. 2010 Jun 25;(25):1-5
pubmed: 20939253
Pediatr Diabetes. 2011 Jun;12(4 Pt 2):442-59
pubmed: 21054719
Diabetes Ther. 2016 Jun;7(2):203-19
pubmed: 27056202
Pediatrics. 2017 Sep;140(3):
pubmed: 28827377
J Pediatr Gastroenterol Nutr. 2018 Oct;67(4):435-436
pubmed: 30239486
Cardiovasc Diabetol. 2020 Jun 13;19(1):79
pubmed: 32534575
N Engl J Med. 2022 May 19;386(20):1877-1888
pubmed: 35373933
J Med Internet Res. 2020 Jan 30;22(1):e16204
pubmed: 32012066
Endocr Pract. 2021 May;27(5):419-425
pubmed: 33934752
Diabet Med. 2019 Nov;36(11):1487-1493
pubmed: 31505060
J Clin Med. 2022 Jan 05;11(1):
pubmed: 35012017
Diabetologia. 2003 Jun;46(6):760-5
pubmed: 12774166
Pediatr Obes. 2014 Aug;9(4):249-59
pubmed: 23776133
Diabetes Care. 2021 Jan;44(1):14-16
pubmed: 33444165
Best Pract Res Clin Endocrinol Metab. 2007 Sep;21(3):415-30
pubmed: 17875489
Diabetes Metab Res Rev. 2020 Jan;36(1):e3211
pubmed: 31352688
Pediatr Diabetes. 2009 Jun;10(4):234-9
pubmed: 19140898
Atherosclerosis. 2018 Jun;273:53-58
pubmed: 29679801
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Child Obes. 2022 Mar;18(2):132-142
pubmed: 34550798
Diabetologia. 2016 Jan;59(1):87-91
pubmed: 26546085
Circulation. 2019 Apr 16;139(16):1900-1912
pubmed: 30798638
Diabetes Care. 2008 Jul;31(7):1360-6
pubmed: 18375412
Diabetes Care. 2009 Aug;32(8):1384-90
pubmed: 19435955
Nutr Metab Cardiovasc Dis. 2007 Jun;17(5):376-82
pubmed: 17562573
Diabetes Care. 2014;37(1):144-8
pubmed: 24062319
Diabetes Care. 2019 Nov;42(11):2050-2056
pubmed: 31488568
Diabetes Metab Res Rev. 2021 Jan;37(1):e3356
pubmed: 32463568
Diabetes Care. 2011 Jan;34 Suppl 1:S89-96
pubmed: 21193633
Diabetes Metab J. 2013 Dec;37(6):458-64
pubmed: 24404517
Diabetes Care. 1999 Jan;22(1):99-111
pubmed: 10333910
BMJ Open Diabetes Res Care. 2021 Dec;9(2):
pubmed: 34969693
Am J Hum Biol. 2001 Sep-Oct;13(5):612-9
pubmed: 11505469
Lancet. 2017 Jun 24;389(10088):2503-2513
pubmed: 28495109